Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.

Abstract:

BACKGROUND:In recent years many therapeutic regimens have been designed in order to improve response rate and response duration in non-Hodgkin's lymphoma (NHL). In 1991 the Italian Lymphoma Study Group (GISL) started a prospective randomized trial on treatment of aggressive and advanced NHL, focused on the efficacy of two Pro-MACE-CytaBom (P-C) derived protocols. METHODS:From April 1991 to March 1993, 243 cases of intermediate and high grade NHL (Groups D-H according to the Working Formulation) in stage I bulky, II-IV have been registered from 19 institutions and randomized to receive 6 courses of either epidoxorubicin, 30 mg/m2 (P-E) or idarubicin, 6 mg/m2 (P-I) containing P-C. The present study deals with the results of an interim analysis of the first 96 cases enrolled up to December 1991 (median follow up of surviving cases 19 months, range 15-23), in terms of overall response rate, toxicity and dose intensity of the two schedules, and overall survival. RESULTS:The overall response rate was: 55 CR (64.0%), 15 PR (17.4%), 5 NR (5.8%) and 11 PG (12.8%). The actuarial survival rate was 61% at 24 months. Hematological and non-hematological toxicity was comparable in the two arms. Dose intensity was high and similar for the two schedules (90% vs 89%). CONCLUSION:This interim analysis demonstrates that in aggressive NHL both P-C derived schedules with epidoxorubicin or idarubicin are effective, safe and well tolerated, also when used in a large multicentric setting.

journal_name

Haematologica

journal_title

Haematologica

authors

Brugiatelli M,Federico M,Gobbi PG,Avanzini P,Callea V,Cavanna L,De Pasquale A,Di Prisco AU,Di Rienzo N,Silingardi V

subject

Has Abstract,Author List Incomplete

pub_date

1993-09-01 00:00:00

pages

306-12

issue

5

eissn

0390-6078

issn

1592-8721

journal_volume

78

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

    abstract::Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE syste...

    journal_title:Haematologica

    pub_type: 杂志文章,实务指引

    doi:10.3324/haematol.2013.099358

    authors: Engelhardt M,Terpos E,Kleber M,Gay F,Wäsch R,Morgan G,Cavo M,van de Donk N,Beilhack A,Bruno B,Johnsen HE,Hajek R,Driessen C,Ludwig H,Beksac M,Boccadoro M,Straka C,Brighen S,Gramatzki M,Larocca A,Lokhorst H,Magar

    更新日期:2014-02-01 00:00:00

  • Patterns of iron distribution in liver cells in beta-thalassemia studied by X-ray microanalysis.

    abstract:BACKGROUND AND OBJECTIVES:beta-thalassemia is an important public health problem in the countries bordering the Mediterranean sea. One of the major consequences of this disorder, primarily (due to an ineffective erythropoiesis) or secondarily to blood transfusions (which are necessary for the patient's survival), is ir...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Faa G,Terlizzo M,Gerosa C,Congiu T,Angelucci E

    更新日期:2002-05-01 00:00:00

  • Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.

    abstract::Eleven patients with advanced APL were treated with ATO (0.15 mg/Kg daily). Eight (73%) achieved molecular CR, but 5 relapsed, 1 died in molecular CR, 1 was lost to follow-up and 1 is still alive in CR after allogeneic transplantation. We suggest that ATO may be effective also in advanced APL, but given the short CR, ...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Carmosino I,Latagliata R,Avvisati G,Breccia M,Finolezzi E,Lo Coco F,Petti MC

    更新日期:2004-05-01 00:00:00

  • Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

    abstract::The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.188227

    authors: Liu A,Li S,Donnenberg V,Fu J,Gollin SM,Ma H,Lu C,Stolz DB,Mapara MY,Monaghan SA,Lentzsch S

    更新日期:2018-10-01 00:00:00

  • In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study.

    abstract::Eight elderly patients with relapsed or refractory acute myeloid leukemia were treated sequentially with recombinant human granulocyte colony-stimulating factor with rhG-CSF and Mylotarg. Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complet...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Leone G,Rutella S,Voso MT,Fianchi L,Scardocci A,Pagano L

    更新日期:2004-05-01 00:00:00

  • Mitotic separation of daughter cells in the human lymphoma B cell line Daudi involves L-selectin engagement and shedding.

    abstract:BACKGROUND AND OBJECTIVE:A novel role for shedding of the surface molecule L-selectin has been proposed as an adjunctive phenomenon during cell detachment from marrow stroma or vessel endothelium. We wished to examine whether variations in expression of L-selectin on a lymphoma B cell line were linked to shedding. DES...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Po JL,Mak A,Ginsberg D,Huerta P,Manoukian R,Shustik C,Jensen GS

    更新日期:1999-09-01 00:00:00

  • The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.

    abstract:BACKGROUND AND OBJECTIVES:Germ cell tumors (GCTs) are very chemosensitive cancers, in which high-dose chemotherapy (HDCT) has been investigated as salvage therapy or as first-line treatment in poor prognosis patients. This paper presents an update of available information in order to define the status of HDCT in GCT pa...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: De Giorgi U,Rosti G,Papiani G,Marangolo M

    更新日期:2002-01-01 00:00:00

  • Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.

    abstract::It is well known that allo-reactive T cells play a crucial role in graft-versus-leukemia and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (alloSCT). Allo-reactive CD4(+) T cells can mediate direct cytolysis, but may also stimulate production of IgG antibodies as helper cells. Immu...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2013.086652

    authors: Kremer AN,van der Griendt JC,van der Meijden ED,Honders MW,Ayoglu B,Schwenk JM,Nilsson P,Falkenburg JH,Griffioen M

    更新日期:2014-02-01 00:00:00

  • B-cell involvement in chronic graft-versus-host disease.

    abstract::Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected. Chronic graft-versus-host disease is an important cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. This a...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.13311

    authors: Kapur R,Ebeling S,Hagenbeek A

    更新日期:2008-11-01 00:00:00

  • Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.

    abstract:BACKGROUND:In multiple myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens which can be classified by varying expression in normal tissue: restricted to testis, ...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3324/haematol.2010.037978

    authors: van Duin M,Broyl A,de Knegt Y,Goldschmidt H,Richardson PG,Hop WC,van der Holt B,Joseph-Pietras D,Mulligan G,Neuwirth R,Sahota SS,Sonneveld P

    更新日期:2011-11-01 00:00:00

  • Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).

    abstract:OBJECTIVES:Perceiving the need for rigorous recommendations to facilitate decisions concerning the management of patients with multiple myeloma (MM), the Italian Society of Hematology (SIE) and the two affiliate societies (SIES and GITMO) commissioned a project to develop guidelines for the therapy of MM using evidence...

    journal_title:Haematologica

    pub_type: 杂志文章,实务指引,评审

    doi:

    authors: Barosi G,Boccadoro M,Cavo M,Corradini P,Marchetti M,Massaia M,Merlini G,Tosi P,Tura S,Italian Society of Hematology.,Italian Society of Experimental Hematology.,Italian Group for Bone Marrow Transplantation.

    更新日期:2004-06-01 00:00:00

  • Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.

    abstract::The discovery that the Ten-Eleven Translocation (TET) hydroxylases cause DNA demethylation has fundamentally changed the notion of how DNA methylation is regulated. Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutations can be early events in hematologic cancers and recent investigation...

    journal_title:Haematologica

    pub_type: 杂志文章,随机对照试验

    doi:10.3324/haematol.2013.088740

    authors: Asmar F,Punj V,Christensen J,Pedersen MT,Pedersen A,Nielsen AB,Hother C,Ralfkiaer U,Brown P,Ralfkiaer E,Helin K,Grønbæk K

    更新日期:2013-12-01 00:00:00

  • Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

    abstract::The prognosis of patients with acute myeloid leukemia in whom primary treatment fails remains very poor. In order to improve such patients' outcome, we conducted a phase 2, prospective, multicenter trial to test the feasibility of a new sequential regimen, combining a short course of intensive chemotherapy and a reduc...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2016.150326

    authors: Mohty M,Malard F,Blaise D,Milpied N,Socié G,Huynh A,Reman O,Yakoub-Agha I,Furst S,Guillaume T,Tabrizi R,Vigouroux S,Peterlin P,El-Cheikh J,Moreau P,Labopin M,Chevallier P

    更新日期:2017-01-01 00:00:00

  • Microenvironmental contributions to hematopoietic stem cell aging.

    abstract::Hematopoietic stem cell (HSC) aging was originally thought to be essentially an HSC-autonomous process, which is the focus of another review in the same issue of Haematologica However, studies on the microenvironment that maintains and regulates HSC (HSC niche) over the past 20 years have suggested that microenvironme...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.2018.211334

    authors: Ho YH,Méndez-Ferrer S

    更新日期:2020-01-01 00:00:00

  • Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.

    abstract::We studied wild-type FLT3 mRNA expression at diagnosis in bone marrow samples from 85 patients with acute myeloid leukemia (AML), 23 of whom were in complete remission, and determined its utility as a marker for minimal residual disease (MRD). We conclude that FLT3 expression is of limited value as a prognostic marker...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Kainz B,Fonatsch C,Schwarzinger I,Sperr WR,Jäger U,Gaiger A

    更新日期:2005-05-01 00:00:00

  • Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.

    abstract::Some prospective studies showed that rabbit antithymocyte globulin was inferior to horse antithymocyte globulin as first-line therapy for patients with severe aplastic anemia. We retrospectively analyzed the clinical outcome of 455 children with severe aplastic anemia who received horse antithymocyte globulin (n=297) ...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2013.089268

    authors: Jeong DC,Chung NG,Cho B,Zou Y,Ruan M,Takahashi Y,Muramatsu H,Ohara A,Kosaka Y,Yang W,Kim HK,Zhu X,Kojima S

    更新日期:2014-04-01 00:00:00

  • Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells.

    abstract:BACKGROUND:Vgamma9Vdelta2 T lymphocytes are regarded as promising mediators of cancer immunotherapy due to their capacity to eliminate multiple experimental tumors, particularly within those of hematopoietic origin. However, Vgamma9Vdelta2 T-cell based lymphoma clinical trials have suffered from the lack of biomarkers ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.020602

    authors: Gomes AQ,Correia DV,Grosso AR,Lança T,Ferreira C,Lacerda JF,Barata JT,Silva MG,Silva-Santos B

    更新日期:2010-08-01 00:00:00

  • Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

    abstract:BACKGROUND:In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied ...

    journal_title:Haematologica

    pub_type: 杂志文章,随机对照试验

    doi:10.3324/haematol.2010.039131

    authors: Buyse M,Michiels S,Squifflet P,Lucchesi KJ,Hellstrand K,Brune ML,Castaigne S,Rowe JM

    更新日期:2011-08-01 00:00:00

  • Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.

    abstract::To our knowledge, there is little information about functional thrombin activatable fibrinolysis inhibitor (TAFI) levels and the risk of acute coronary artery disease (CAD). We investigated the risk of acute CAD related to plasma levels of functional TAFI. We found that functional TAFI levels in plasma (above 126%), i...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Santamaría A,Martínez-Rubio A,Borrell M,Mateo J,Ortín R,Fontcuberta J

    更新日期:2004-07-01 00:00:00

  • Aberrant expression of microRNA in polycythemia vera.

    abstract:BACKGROUND:Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis. Because microRNA regulate hematopoietic differentiation, we hypothesized that dysregul...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12706

    authors: Bruchova H,Merkerova M,Prchal JT

    更新日期:2008-07-01 00:00:00

  • Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report.

    abstract::Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0-17.9 years treated for acute lymphobl...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.199356

    authors: Wolthers BO,Frandsen TL,Patel CJ,Abaji R,Attarbaschi A,Barzilai S,Colombini A,Escherich G,Grosjean M,Krajinovic M,Larsen E,Liang DC,Möricke A,Rasmussen KK,Samarasinghe S,Silverman LB,van der Sluis IM,Stanulla M,Tulstr

    更新日期:2019-03-01 00:00:00

  • Interferon-alpha 2b is not effective in the treatment of refractory immune thrombocytopenic purpura.

    abstract::About 25-30% of patients with immune thrombocytopenic purpura (ITP) are refractory to corticosteroids, splenectomy and other treatments. It has been suggested that interferon-alpha 2b (IFN-alpha 2b) may be useful in the treatment of chronic refractory ITP patients. We treated 9 chronic refractory ITP patients with IFN...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Vianelli N,Tazzari PL,Baravelli S,Ricci F,Valdrè L,Tura S

    更新日期:1998-08-01 00:00:00

  • Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

    abstract::Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2017.169656

    authors: Younes A,Salles G,Martinelli G,Bociek RG,Barrigon DC,Barca EG,Turgut M,Gerecitano J,Kong O,Pisal CB,Tavorath R,Kim WS

    更新日期:2017-12-01 00:00:00

  • Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study.

    abstract::Next-generation sequencing (NGS) has transitioned from research to clinical routine, yet the comparability of different technologies for mutation profiling remains an open question. We performed a European multicenter (n=6) evaluation of three amplicon-based NGS assays targeting 11 genes recurrently mutated in chronic...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.234716

    authors: Sutton LA,Ljungström V,Enjuanes A,Cortese D,Skaftason A,Tausch E,Stano Kozubik K,Nadeu F,Armand M,Malcikova J,Pandzic T,Forster J,Davis Z,Oscier D,Rossi D,Ghia P,Strefford JC,Pospisilova S,Stilgenbauer S,Davi F,Ca

    更新日期:2020-04-09 00:00:00

  • Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

    abstract::Children with immune thrombocytopenia for ≥6 months completing a romiplostim study received weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×109/L) in this extension to examine romiplostim's long-term safety and efficacy. Sixty-five children received romiplostim for a median of 2.6 years...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.202283

    authors: Tarantino MD,Bussel JB,Blanchette VS,Beam D,Roy J,Despotovic J,Raj A,Carpenter N,Mehta B,Eisen M

    更新日期:2019-11-01 00:00:00

  • Autologous blood stem cell transplantation in hematologic malignancies.

    abstract::Circulating stem cells (CSC) are well documented in animals and humans. Though their function in normal conditions remains obscure, autologous CSC seem capable of restoring hemopoiesis after myeloablative treatment. With cell separators CSC may be harvested in adequate number, and collection may be further improved gi...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Majolino I,Scimé R,Indovina A

    更新日期:1990-11-01 00:00:00

  • Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

    abstract:BACKGROUND AND OBJECTIVES:Chromosome 5 and/or 7 abnormalities are cytogenetic findings indicative of a poor prognosis in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The only potential cure for such patients is allogeneic stem cell transplantation (SCT). As data on allogeneic SCT in thi...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: van der Straaten HM,van Biezen A,Brand R,Schattenberg AV,Egeler RM,Barge RM,Cornelissen JJ,Schouten HC,Ossenkoppele GJ,Verdonck LF,Netherlands Stem Cell Transplant Registry \TYPHON\.

    更新日期:2005-10-01 00:00:00

  • Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.

    abstract::Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatme...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.159160

    authors: Bi C,Zhang X,Lu T,Zhang X,Wang X,Meng B,Zhang H,Wang P,Vose JM,Chan WC,McKeithan TW,Fu K

    更新日期:2017-04-01 00:00:00

  • Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.

    abstract::We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficac...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Baudo F,de Cataldo F,Gaidano G,Italian registry of acquired hemophilia.

    更新日期:2004-06-01 00:00:00

  • Peering through zebrafish to understand inherited bone marrow failure syndromes.

    abstract::Inherited bone marrow failure syndromes are experiments of nature characterized by impaired hematopoiesis with cancer and leukemia predisposition. The mutations associated with inherited bone marrow failure syndromes affect fundamental cellular pathways, such as DNA repair, telomere maintenance, or proteostasis. How t...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.2018.196105

    authors: Oyarbide U,Topczewski J,Corey SJ

    更新日期:2019-01-01 00:00:00